Bioxytran Provides Corporate Update Highlighting Momentum Across Its Multi-Platform Pipeline
Company reiterates focus on advancing ProLectin‑M under an active FDA IND and progressing oxygen-transport programs for stroke and neurodegenerative diseases. Needham, Massachusetts, United States, January 29, 2026 — Bioxytran, Inc. (OTCQB: BIXT) (“Bioxytran” or the… Read More »Bioxytran Provides Corporate Update Highlighting Momentum Across Its Multi-Platform Pipeline





